Related Experiment Videos
Towards an RNA-based therapy for Marfan syndrome
M W Kilpatrick1, L A Phylactou
1Dept of Pediatrics, University of Connecticut Health Center, Farmington 06030, USA. kilpatrick@sun.uchc.edu
Molecular Medicine Today
|October 29, 1998
Summary
Gene therapy for dominant genetic disorders like Marfan syndrome faces challenges. Antisense hammerhead ribozymes show promise for suppressing disease-causing mutant fibrillin 1 RNA, offering a potential Marfan syndrome treatment.
Area of Science:
- Molecular Biology
- Genetics
- Biochemistry
Background:
- Dominant genetic disorders pose challenges for gene therapy.
- Therapies often require suppressing the disease allele while preserving the wild-type gene.
- Marfan syndrome, a connective tissue disorder, results from dominant-negative mutant fibrillin 1.
Purpose of the Study:
- To explore the potential of antisense hammerhead ribozymes as a therapeutic strategy for Marfan syndrome.
- To investigate the feasibility of targeting and cleaving mutant fibrillin 1 RNA.
Main Methods:
- Utilizing antisense hammerhead ribozymes, which are catalytic RNAs.
- Designing ribozymes to specifically target and cleave the RNA transcript of the mutant fibrillin 1 gene.
Main Results:
- Antisense hammerhead ribozymes demonstrate potential for specific RNA targeting and cleavage.
- This approach could enable suppression of the disease-causing allele in dominant disorders.
Conclusions:
- Antisense hammerhead ribozymes represent a promising therapeutic avenue for Marfan syndrome.
- This strategy offers a potential method for managing dominant genetic disorders by allele-specific RNA suppression.